Mifcare announced having received the support of HTaPFrance aiming to Promote Research and Development of New Therapies against PAH

The French patients’ association HTaPFrance, new support for Mifcare in the fight against PAH

Paris, March 14, 2017 – Mifcare, a privately held biotechnology company developing breakthrough anti-inflammatory therapeutics for the treatment of pulmonary arterial hypertension (PAH), announced today having received the support of HTaPFrance, the French pulmonary hypertension association.

The support of HTaPFrance aims to promote research and development of new therapies to better fight PAH, a rare and life-threatening disease, whose impact is significant in terms of disability on patients’ daily lives.

This new support adds up to that of Inserm U999 (Inserm/University of Paris-Sud), a world-renowned laboratory specialized in PAH and led by Pr Marc Humbert, with which Mifcare collaborates.

“Promoting research against PAH is one of the missions of our association, which is why, as Director of HTaPFrance, I do not hesitate to give my full support, and through mine, that of our association, to the biotechnology start-up Mifcare” explains Melanie Gallant-Dewavrin, Director of the French pulmonary hypertension association HTaPFrance.

“The support of the French patients’ association HTaPFrance to Mifcare is extremely important and fully in line with the mission that we have set, which is to develop innovative small molecules to better counteract the narrowing of the small pulmonary arteries leading to the development and progression of PAH. MFC1040 targeting the pleiotropic cytokine MIF (macrophage migration inhibitory factor), currently in preclinical phase, is our most advanced product” details Dr Gael Jalce, CEO and Co-Founder at Mifcare.

About PAH

Pulmonary arterial hypertension (PAH) is a severe and incurable disease characterized by progressive narrowing of the small pulmonary arteries leading to an abnormal increase in pulmonary vascular resistance and pulmonary blood pressure and, ultimately right ventricular heart failure. Although the exact mechanisms leading to the onset and progression of PAH are still not yet fully understood, inflammation in and around the pulmonary arteries is strongly suspected to facilitate the development of the disease.

About HTaPFrance

Founded in 1996, HTaPFrance is a French national association under the law of 1901, that proposes: i) aid for patients suffering from pulmonary arterial hypertension, a progressive and disabling disease, source of severe handicaps, ii) aid and support to the families and relatives of these patients, and (iii) help to improve the conditions of daily life with this disease. As such, it aims to represent patients with PAH. It takes part and helps in medical and scientific research on this disease and its therapies. It informs about the origins of the disease, the different therapies, and its management. It aims to connect patients, doctors, public authorities, health policies, administrations, pharmaceutical
Press release

companies, service providers, associations and other stakeholders in PAH. For more information, please visit www.htapfrance.com.

About Inserm U999

Inserm U999 headed by Marc Humbert, MD, PhD, is focused on pathophysiology and clinical management of pulmonary arterial hypertension (PAH). Composed of high level scientists, Inserm U999 studies molecular pathways causing pulmonary vascular remodeling in human and experimental models of pulmonary hypertension, identifies targets for therapy, fosters drug development based on these targets and tests novel treatments. Inserm U999 is located at both Marie Lannelongue Hospital and Bicêtre Hospital. For more information, please go to www.u999.up-sud.fr/fr/.

About Mifcare

Mifcare is a privately held biotechnology company developing breakthrough anti-inflammatory therapeutics with a primary focus on pulmonary arterial hypertension (PAH). The company is specialized in the discovery and development of new small molecule antagonists of macrophage migration inhibitory factor (MIF), a pleiotropic factor that modulates pro-inflammatory immune responses. Mifcare has established a strategic collaboration in the field of PAH with Inserm U999, a world-renowned academic laboratory specialized in this disease. The company is headquartered in Paris, France. For more information about Mifcare, please visit www.mifcare.com or https://www.linkedin.com/company/mifcare.

Contact

Corporate and Media Contact
Gael Jalce, PhD
Chief Executive Officer
+33 6 142 105 42
contact@mifcare.com